CTSH

Across TCGA pan-cancer cohorts, CTSH mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated CTSH data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CTSH mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CTSH expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

HNSC, LUAD, and COAD are the cancer types where CTSH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.559	0.899	.001	68	view →
LUAD	OS	Median	All	0.895	0.612	<.001	57	view →
COAD	DFS	Median	II,III,IV	0.876	1.000	.015	36	view →
LSCC	DFS	Quartile	All	0.574	0.907	.008	27	view →
GBM	OS	Median	All	0.396	0.684	.001	8	view →
CCRCC	OS	Tertile	All	1.000	0.907	.015	7	view →
UCEC	DFS	Tertile	III,IV	0.491	1.000	.042	4	view →
PDAC	OS	Tertile	IV	0.472	0.934	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

CTSH–HNSC (DFS)

Open the HNSC breakdown →